恒瑞医药宫颈癌疗法获批
2026-07-23 12:22:24
据界面新闻报道，近日，恒瑞医药及子公司苏州盛迪亚生物医药有限公司收到中国国家药品监督管理局通知，批准艾比特®（苹果酸法米替尼）联合艾瑞卡®（注射用卡瑞利珠单抗）用于PD-L1表达阳性、复发或转移性宫颈癌患者的一线治疗。该疗法此前已用于晚期宫颈癌二线治疗。
Disclaimer:
1. The information provided does not constitute investment advice. Investors should make independent decisions and bear all risks themselves.
2. The copyright of this content belongs to the original author. The views expressed herein are solely those of the author and do not represent the stance or position of this website.
Previous article：
欧央行维持利率2.25%不变以评估伊朗战争通胀影响；9月加息几乎板上钉钉Next article：
南非基金拟募60.9亿美元风投
